iShares 0 3 Month Treasury Bond ETF vs Tilray Brands Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.49, while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| SGOV | TLRY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $100.72 | $21.00 |
52-Week Low | $100.28 | $3.88 |
Market Cap | — | $591.60M |
Enterprise Value | — | $758.73M |
Signals from Pluang's Aura AI — not financial advice
SGOV trades at $100.475 with minimal daily movement, showing price stability amid bearish technical signals. The ETF maintains consistent dividend distributions with recent payouts of $0.30-$0.31 per share. Technical indicators show strong bearish momentum with 17 sell signals versus 3 buy signals, though RSI levels suggest potential oversold conditions. Market sentiment reflects broader Treasury market concerns as rising oil prices fuel inflation worries.
The outlook remains cautious given the bearish technical picture and macroeconomic headwinds from rising Treasury yields. Investors seeking Treasury exposure may find value in SGOV's stability and dividend consistency, though the current environment of rising rates and inflation pressures presents near-term challenges for fixed income ETFs.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →